{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:23:40Z","timestamp":1783632220099,"version":"3.55.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hidradenitis suppurativa (HS) is associated with a substantial disease burden. Given the complex nature of HS-related symptoms, patient-reported outcome (PRO) measures are important to ensure that the patient experience is captured when evaluating the efficacy of treatments in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To develop the Hidradenitis Suppurativa Symptom and Impact Diary (HSSID\u00a9), a novel PRO measure for use in clinical trials to assess the symptoms and impacts of HS in adult patients, and to validate its psychometric properties.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The development phase involved patients with HS and clinicians with HS expertise and included three sequential stages: (i) concept elicitation interviews (n = 8); (ii) item development; and (iii) cognitive debriefing interviews (n = 12). The psychometric properties of the HSSID were evaluated using data from a subset of patients participating in the SUNSHINE (NCT03713619) and SUNRISE (NCT03713632) trials, and included assessments of reliability, validity and ability to detect change. Anchor-based methods to estimate meaningful change thresholds were explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The HSSID comprises 11 items; 5 relate to HS symptoms (lesion-related pain, lesion-related itching, lesion drainage, odour and physical fatigue) and 6 to HS impacts (ability to walk, ability to move [other than walking], sleep disturbance, time spent with other people, negative impact on emotions and ability to complete work). Patients found the HSSID items easy to understand and reported no difficulties recalling symptoms\/impacts experienced in the previous 24\u2005h. Overall, 478 patients from SUNSHINE and SUNRISE were included in the psychometric evaluation phase. Good association with low redundancy was observed among HSSID items with moderate (&amp;gt; 0.30) to strong (&amp;gt; 0.50) inter-diary item correlations among symptoms and impact items, and across groups. Test\u2013retest reliability estimates in stable subsets were high across SUNSHINE and SUNRISE, ranging from 0.78 to 0.96. Construct validity analysis confirmed that each HSSID item correlated with \u2265 1 targeted support variable. HSSID item scores demonstrated satisfactory responsiveness to detect change; however, anchor-based meaningful change thresholds could be established for the worst lesion-related pain item only.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The HSSID appropriately assesses the symptoms and impacts of HS in adults. HSSID items demonstrated generally robust psychometric properties.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf307","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T11:24:04Z","timestamp":1754306644000},"page":"1155-1164","source":"Crossref","is-referenced-by-count":2,"title":["The Hidradenitis Suppurativa Symptom and Impact Diary: Development and psychometric evaluation of a novel set of patient-reported outcomes for hidradenitis suppurativa"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-1142","authenticated-orcid":false,"given":"John R","family":"Ingram","sequence":"first","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University , Cardiff ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena B","family":"Wozniak","sequence":"additional","affiliation":[{"name":"Novartis Ireland Limited , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Passera","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Uhlmann","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Llobet","family":"Martinez","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0418-521X","authenticated-orcid":false,"given":"Falk G","family":"Bechara","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum , Bochum ,","place":["Germany"]},{"name":"International Center for Hidradenitis Suppurativa\/Acne Inversa (ICH), Ruhr-University Bochum ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5565-4712","authenticated-orcid":false,"given":"Randall H","family":"Bender","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park , NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7837-8033","authenticated-orcid":false,"given":"Lori D","family":"McLeod","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park , NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9594-5036","authenticated-orcid":false,"given":"Susan","family":"Martin","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park , NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6341-7546","authenticated-orcid":false,"given":"Santiago G","family":"Moreno","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-5865","authenticated-orcid":false,"given":"Jessica","family":"Marvel","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation , East Hanover, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoba","family":"Ravichandran","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation , East Hanover, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa B","family":"Kimball","sequence":"additional","affiliation":[{"name":"Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"2025111813170280200_ljaf307-B1","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis","volume":"82","author":"Goldburg","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025111813170280200_ljaf307-B2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025111813170280200_ljaf307-B3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1203475417746122","article-title":"Surgical treatment of sinus tracts and fistulas in perianal hidradenitis suppurativa","volume":"22","author":"Scholl","year":"2018","journal-title":"J\u00a0Cutan Med Surg"},{"key":"2025111813170280200_ljaf307-B4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMcp1014163","article-title":"Clinical practice. Hidradenitis suppurativa","volume":"366","author":"Jemec","year":"2012","journal-title":"N Engl J Med"},{"key":"2025111813170280200_ljaf307-B5","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/jdv.18163","article-title":"Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US","volume":"36","author":"Ingram","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025111813170280200_ljaf307-B6","doi-asserted-by":"crossref","first-page":"e030579","DOI":"10.1136\/bmjopen-2019-030579","article-title":"Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data","volume":"9","author":"Marvel","year":"2019","journal-title":"BMJ Open"},{"key":"2025111813170280200_ljaf307-B7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/AJP.0b013e3181ceb80c","article-title":"Painful hidradenitis suppurativa","volume":"26","author":"Smith","year":"2010","journal-title":"Clin J Pain"},{"key":"2025111813170280200_ljaf307-B8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11916-017-0647-3","article-title":"Pain, psychological comorbidities, disability, and impaired quality of life in hidradenitis suppurativa [corrected]","volume":"21","author":"Patel","year":"2017","journal-title":"Curr Pain Headache Rep"},{"key":"2025111813170280200_ljaf307-B9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2340\/00015555-2815","article-title":"Clinical characteristics of pruritus and pain in patients with hidradenitis suppurativa","volume":"98","author":"Matusiak","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"2025111813170280200_ljaf307-B10","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bjd.21821","article-title":"Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: a scoping review to inform pain measurement in hidradenitis suppurativa","volume":"187","author":"Hasan","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025111813170280200_ljaf307-B11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jid.2017.09.008","article-title":"Increased suicide risk in patients with hidradenitis suppurativa","volume":"138","author":"Thorlacius","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2025111813170280200_ljaf307-B12","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamadermatol.2019.0759","article-title":"Depression and anxiety in adults with hidradenitis suppurativa: a systematic review and meta-analysis","volume":"155","author":"Machado","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2025111813170280200_ljaf307-B13","doi-asserted-by":"crossref","first-page":"13030\/qt4rm8w7kn","DOI":"10.5070\/D3269050156","article-title":"Physical symptoms and psychosocial problems associated with hidradenitis suppurativa: correlation with Hurley stage","volume":"26","author":"McKenzie","year":"2020","journal-title":"Dermatol Online J"},{"key":"2025111813170280200_ljaf307-B14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s13555-023-01085-w","article-title":"Burden of hidradenitis suppurativa: a systematic literature review of patient reported outcomes","volume":"14","author":"Kimball","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025111813170280200_ljaf307-B15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/ajd.13910","article-title":"The impact of hidradenitis suppurativa on quality of life is worse than inflammatory bowel disease and myocardial infarction","volume":"63","author":"Mortimore","year":"2022","journal-title":"Australas J Dermatol"},{"key":"2025111813170280200_ljaf307-B16","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/bjd.15280","article-title":"The burden of common skin diseases assessed with the EQ5D: a European multicentre study in 13 countries","volume":"176","author":"Balieva","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025111813170280200_ljaf307-B17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.12788\/j.sder.2017.022","article-title":"Complications of hidradenitis suppurativa","volume":"36","author":"Yuan","year":"2017","journal-title":"Semin Cutan Med Surg"},{"key":"2025111813170280200_ljaf307-B18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000502139","article-title":"Pruritus and malodour in patients with hidradenitis suppurativa: impact on quality of life and clinical features associated with symptom severity","volume":"236","author":"Molina-Leyva","year":"2020","journal-title":"Dermatology"},{"key":"2025111813170280200_ljaf307-B19","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.16672","article-title":"A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025111813170280200_ljaf307-B20","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"2025111813170280200_ljaf307-B21","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/jdv.15519","article-title":"Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa","volume":"33","author":"Chernyshov","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025111813170280200_ljaf307-B22","author":"U.S. Department of Health and Human Services"},{"key":"2025111813170280200_ljaf307-B23","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1002\/ski2.214","article-title":"Quality of life in hidradenitis suppurativa (acne inversa): a scoping review","volume":"3","author":"Kaur","year":"2023","journal-title":"Skin Health Dis"},{"key":"2025111813170280200_ljaf307-B24","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/bjd.19344","article-title":"Validation of global item for assessing impact on quality of life of patients with hidradenitis suppurativa","volume":"184","author":"Kirby","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025111813170280200_ljaf307-B25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09546634.2017.1341614","article-title":"Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa","volume":"29","author":"Kimball","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"2025111813170280200_ljaf307-B26","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bjd.18692","article-title":"The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials","volume":"183","author":"Kirby","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025111813170280200_ljaf307-B27","doi-asserted-by":"crossref","first-page":"adv00859","DOI":"10.2340\/actadv.v102.2485","article-title":"Measuring quality of life in hidradenitis suppurativa: development and validation of a disease-specific patient-reported outcome measure for practice and research","volume":"103","author":"Otten","year":"2023","journal-title":"Acta Derm Venereol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf307\/63960976\/ljaf307.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/6\/1155\/63960976\/ljaf307.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/6\/1155\/63960976\/ljaf307.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T18:17:11Z","timestamp":1763489831000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/193\/6\/1155\/8222695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,8,5]]},"published-print":{"date-parts":[[2025,11,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf307","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,8,5]]}}}